None
EN
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
[]
BizToc
1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter.
A copy of the letter can be downloaded here.
1 Main Capital Partners returned 15.0% in Q2 2026, compared to 15.2% and 21.6% for the S&P 500 (SPX) and Russell 2000 (RTY), respectively.…This story appeared on finance.yahoo.com , 2026-08-03 15:09:16.